Dyne Therapeutics Stock Analysis
| DYN Stock | USD 15.55 0.00 0.00% |
IPO Date 17th of September 2020 | 200 Day MA 14.8596 | 50 Day MA 18.4615 | Beta 1.312 |
Dyne Therapeutics holds a debt-to-equity ratio of 0.114. As of the 16th of February 2026, Short and Long Term Debt Total is likely to drop to about 20.5 M. In addition to that, Net Debt is likely to grow to about (351.8 M) With a high degree of financial leverage come high-interest payments, which usually reduce Dyne Therapeutics' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Dyne Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Dyne Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Dyne Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Dyne Therapeutics' stakeholders.
For many companies, including Dyne Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Dyne Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Dyne Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 3.6987 | Book Value 4.851 | Enterprise Value | Enterprise Value Ebitda (8.87) | Shares Float 134.2 M |
Dyne Therapeutics is undervalued with Real Value of 20.86 and Target Price of 39.13. The main objective of Dyne Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dyne Therapeutics is worth, separate from its market price. There are two main types of Dyne Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dyne Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Dyne Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Dyne Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. Dyne Stock Analysis Notes
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Dyne Therapeutics was currently reported as 4.85. The company has Price/Earnings To Growth (PEG) ratio of 0.19. Dyne Therapeutics recorded a loss per share of 3.62. The entity last dividend was issued on the May 30, 2002. The firm had 1:5 split on the May 25, 2010. Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.. Dyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people. To learn more about Dyne Therapeutics call Joshua Brumm at 781 786 8230 or check out https://www.dyne-tx.com.Dyne Therapeutics Investment Alerts
| Dyne Therapeutics generated a negative expected return over the last 90 days | |
| Dyne Therapeutics has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (317.42 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne Therapeutics has about 291.84 M in cash with (292.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Dyne Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Dyne Therapeutics, Inc. Stock Analysis Unveiling A 130 percent Potential Upside - DirectorsTalk Interviews |
Dyne Largest EPS Surprises
Earnings surprises can significantly impact Dyne Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-12-31 | 2017-12-31 | -0.42 | -0.35 | 0.07 | 16 | ||
2023-03-02 | 2022-12-31 | -0.84 | -0.74 | 0.1 | 11 | ||
2021-05-06 | 2021-03-31 | -0.6 | -0.5 | 0.1 | 16 |
Dyne Therapeutics Environmental, Social, and Governance (ESG) Scores
Dyne Therapeutics' ESG score is a quantitative measure that evaluates Dyne Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Dyne Therapeutics' operations that may have significant financial implications and affect Dyne Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Dyne Stock Institutional Investors
| Shares | Jpmorgan Chase & Co | 2025-06-30 | 3.1 M | Armistice Capital, Llc | 2025-06-30 | 2.6 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.4 M | Geode Capital Management, Llc | 2025-06-30 | 2.3 M | Perceptive Advisors Llc | 2025-06-30 | 2.2 M | Vr Adviser, Llc | 2025-06-30 | 2.2 M | Logos Global Management Lp | 2025-06-30 | 1.9 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 1.8 M | Rtw Investments, Llc | 2025-06-30 | 1.7 M | Ra Capital Management, Llc | 2025-06-30 | 9.7 M | Hhg Plc | 2025-06-30 | 9.4 M |
Dyne Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 2.56 B.Dyne Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.58) | (0.61) |
Management Efficiency
Dyne Therapeutics has Return on Asset of (0.3432) % which means that on every $100 spent on assets, it lost $0.3432. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6066) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of February 2026, Return On Tangible Assets is likely to drop to -0.55. In addition to that, Return On Capital Employed is likely to drop to -0.64. As of the 16th of February 2026, Total Current Assets is likely to grow to about 1 B, while Total Assets are likely to drop about 591 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.69 | 11.85 | |
| Tangible Book Value Per Share | 7.69 | 10.25 | |
| Enterprise Value Over EBITDA | (6.59) | (6.26) | |
| Price Book Value Ratio | 3.17 | 3.36 | |
| Enterprise Value Multiple | (6.59) | (6.26) | |
| Price Fair Value | 3.17 | 3.36 | |
| Enterprise Value | 804.5 M | 764.3 M |
The strategic vision of Dyne Therapeutics management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Technical Drivers
As of the 16th of February 2026, Dyne Therapeutics shows the Variance of 18.18, standard deviation of 4.26, and Mean Deviation of 3.1. Dyne Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Dyne Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Dyne Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Dyne Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Dyne Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dyne Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dyne Therapeutics Outstanding Bonds
Dyne Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dyne Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dyne bonds can be classified according to their maturity, which is the date when Dyne Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dyne Therapeutics Predictive Daily Indicators
Dyne Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dyne Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0617 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 16.02 | |||
| Day Typical Price | 15.86 | |||
| Market Facilitation Index | 1.02 | |||
| Price Action Indicator | (0.47) |
Dyne Therapeutics Corporate Filings
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of January 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 23rd of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 10th of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 8th of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
Dyne Therapeutics Forecast Models
Dyne Therapeutics' time-series forecasting models are one of many Dyne Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dyne Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Dyne Therapeutics Bond Ratings
Dyne Therapeutics financial ratings play a critical role in determining how much Dyne Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Dyne Therapeutics' borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (5.61) | Unlikely Manipulator | View |
Dyne Therapeutics Debt to Cash Allocation
As Dyne Therapeutics follows its natural business cycle, the capital allocation decisions will not magically go away. Dyne Therapeutics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Dyne Therapeutics has 23.99 M in debt with debt to equity (D/E) ratio of 0.11, which may show that the company is not taking advantage of profits from borrowing. Dyne Therapeutics has a current ratio of 11.4, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. That said, strategic use of leverage may enable Dyne to fund expansion initiatives and generate superior returns. Dyne Therapeutics Total Assets Over Time
Dyne Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Dyne Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Dyne Therapeutics Debt Ratio | 2.97 |
Dyne Therapeutics Corporate Bonds Issued
Dyne Short Long Term Debt Total
Short Long Term Debt Total |
|
About Dyne Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Dyne Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dyne shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dyne Therapeutics. By using and applying Dyne Stock analysis, traders can create a robust methodology for identifying Dyne entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.22) | (1.16) | |
| Operating Profit Margin | (0.94) | (0.89) | |
| Net Profit Margin | 0.17 | 0.18 | |
| Gross Profit Margin | (5.51) | (5.79) |
Current Dyne Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dyne analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dyne analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 39.13 | Strong Buy | 14 | Odds |
Most Dyne analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dyne stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dyne Therapeutics, talking to its executives and customers, or listening to Dyne conference calls.
Dyne Stock Analysis Indicators
Dyne Therapeutics stock analysis indicators help investors evaluate how Dyne Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dyne Therapeutics shares will generate the highest return on investment. By understating and applying Dyne Therapeutics stock analysis, traders can identify Dyne Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 123.9 M | |
| Total Stockholder Equity | 629.8 M | |
| Capital Lease Obligations | 24 M | |
| Property Plant And Equipment Net | 30 M | |
| Cash And Short Term Investments | 642.3 M | |
| Net Invested Capital | 629.8 M | |
| Cash | 435.4 M | |
| 50 Day M A | 18.4615 | |
| Net Interest Income | 26.9 M | |
| Total Current Liabilities | 42.3 M | |
| Investments | -204.1 M | |
| Stock Based Compensation | 45.9 M | |
| Common Stock Shares Outstanding | 94.1 M | |
| Total Cashflows From Investing Activities | -204.1 M | |
| Free Cash Flow | -294.7 M | |
| Other Current Assets | 17 M | |
| Accounts Payable | 6.6 M | |
| Net Debt | -411.5 M | |
| Other Operating Expenses | 343.9 M | |
| Non Current Assets Total | 32 M | |
| Liabilities And Stockholders Equity | 691.2 M | |
| Non Currrent Assets Other | 1.9 M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.